DSIP
5mg per vial
Nonapeptide isolated from mammalian brain. Investigated for delta-wave sleep induction and stress-response modulation in animal models.
≥99.50% HPLC
$13.00 / mg
Out of stock
Verified purity
For research use only. Not for human consumption. By purchasing this product, you confirm it will be used solely for legitimate research purposes.
Embedded on every product page
Calculate your dose.
Prefilled from the research protocol for the selected product. Pick a chip or type a custom dose.
DSIP
Vial size
5 mg
BAC water
Dose
2.50
mg/mL concentration
10.0
units per dose
20
doses per vial
Research protocol default: 250mcg, 2mL BAC water
For research reference only. Not medical advice.
Nonapeptide isolated from mammalian brain. Investigated for delta-wave sleep induction and stress-response modulation in animal models.
Overview
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid endogenous neuropeptide first isolated in 1977 by Monnier, Schoenenberger and colleagues from the cerebral venous blood of rabbits in electrically induced slow-wave sleep. It has been investigated in published animal research for its role in delta-wave sleep architecture and stress-response pathways.
This vial contains 5mg of DSIP as a lyophilised powder for reconstitution with sterile diluent in the laboratory.
What is DSIP?
DSIP is a small endogenous peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was named for the observation that its infusion into rabbits in behavioural experiments appeared to increase the proportion of delta-wave activity on electroencephalography recordings during sleep.
Published animal research has investigated DSIP in the context of:
Mechanism of Action
The precise molecular mechanism of DSIP is still poorly characterised in the published literature. It does not appear to bind a single well-defined receptor in the way many neuropeptides do, and its central nervous system effects in animal models have been studied across multiple signalling pathways, including those involving the hypothalamic-pituitary axis.
Early pharmacokinetic work describes a short serum half-life and rapid tissue distribution, which is a central consideration in protocol design for any follow-up research.
Published Research
Selected areas of published preclinical research include:
Human clinical data is limited and largely historical. DSIP is not approved by the TGA or FDA for any therapeutic indication.
Quality and Verification
Every batch ships with a batch-specific Certificate of Analysis documenting purity by HPLC (≥99%) and mass spectrometry confirmation of peptide identity. The vial is shipped lyophilised to preserve stability during transit and should be stored at -20°C prior to reconstitution and 2-8°C after reconstitution in the laboratory.
Further Reading
For background on handling lyophilised research peptides, see our reconstitution calculator.
Disclaimer
For research use only. Not for human consumption. The information provided is for educational and research purposes only. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult published peer-reviewed literature before designing research protocols.
